Kevin J. Freise

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Shaji Kumar, Simon J. Harrison, Michèle Cavo et al. · The Lancet Oncology · 2020 · 390 citations

Hematological Malignancy, Oncology, Hematology +7

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts et al. · Blood · 2017 · 271 citations · Full text

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Sarina A. Piha‐Paul, Jasgit C. Sachdev, Minal Barve et al. · Clinical Cancer Research · 2019 · 156 citations

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Anita D’Souza, Nina Shah, Cesar Rodriguez et al. · Journal of Clinical Oncology · 2022 · 115 citations · Full text

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

Aksana K. Jones, Kevin J. Freise, Suresh Agarwal et al. · The AAPS Journal · 2016 · 99 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9